MLYS Share Trading at $25.56 Amid Potential FDA Approval

AI Summary

Mineralys Therapeutics, Inc. (MLYS) shares were trading at $25.56 as of April 29. The company is awaiting FDA approval for lorundrostat, which could address the large market of 10-12 million patients in the U.S. with resistant hypertension. Despite trading at a market capitalization of approximately $2.5B, MLYS has seen a 36% decline from prior highs. Analysts project that lorundrostat could yield peak sales of roughly $900 million, with EBIT potentially reaching $550-600 million, indicating a valuation disconnect that warrants consideration for investors.